背景:本研究的目的是评估肿瘤大小和睾丸网浸润对I期睾丸精原细胞瘤患者无进展生存期的影响。还进行了文献综述。
方法:进行回顾性观察性研究。我们纳入了2010年1月至2022年7月的I期精原细胞瘤患者。将无不良预后因素的A组患者与有不良预后因素的B组患者进行比较。使用Kaplan-Meier曲线和对数秩检验来比较这些组之间的无进展生存期(PFS)。在P≤0.05时考虑统计学显著性。
结果:55例患者纳入本研究。20例(36.4%)患者预后良好-A组,35例(63.6%)患者预后不良-B组。两组的平均年龄相似(平均值±标准差),38.62±9.04年。平均随访时间为63.5±33.6个月。A组所有患者和B组25.7%的患者均接受了主动监测(AS)。B组患者中有26例(74.3%)接受了一个周期的卡铂治疗。3例腹膜后淋巴结复发(10.3%),他们都用三个周期的BEP治疗,与疾病的完全反应。A组和B组之间的PFS没有发现统计学上的显著差异(log秩P=.317)。
结论:I期精原细胞瘤的个体化辅助治疗很重要,避免由此产生的不利影响。
BACKGROUND: The aim of this
study was to evaluate the impact of tumour size and rete testis invasion in progression free survival of our patients with stage I testicular seminoma. A literature review is also made.
METHODS: A retrospective observational
study was performed. We included patients with stage I seminoma between January 2010 and July 2022. Patients without factors of poor prognostic -Group A- were compared with patients with factors of poor prognostic -Group B-. Kaplan-Meier curves and log-rank testing were used to compare progression free survival (PFS) between these groups. Statistical significance was considered at P≤.05.
RESULTS: 55 patients were included in this
study. 20 patients (36.4%) were of good prognostic -Group A- and 35 (63.6%) had factors of poor prognostic -Group B-. The mean age was similar in both groups (mean±standard deviation), 38.62±9.04 years. The mean follow-up time was 63.5±33.6 months. All the patients in group A and 25.7% of the patients in group B underwent active surveillance (AS). 26 patients (74.3%) of the patients in Group B were treated with one cycle of adyuvant carboplatin. Three patients suffered a relapse with retroperitoneal lymph nodes (10.3%), all of them were treated with three cycles of BEP, with a complete response of the disease. No statistical significant differences were found in PFS between Group A and B (log Rank P=.317).
CONCLUSIONS: Individualization of adjuvant treatment in stage I seminoma is important, avoiding the adverse effects derived from them.